Abstract
The human complement receptor type 2/factor H fusion protein TT30, an alternative pathway specific complement inhibitor, prevents hemolysis of erythrocytes from patients with paroxysmal nocturnal hemoglobinuria by membrane-targeting of factor H activity
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have